Australia Determined To Forcibly Vaccinate Intentional, Controlled Release of Aerosolized GMO Vaccine

Posted by in Blog | Comments Off on Australia Determined To Forcibly Vaccinate Intentional, Controlled Release of Aerosolized GMO Vaccine

The Office of the Gene Technology Regulator (OGTR) is on its way to approve a   licence application from PaxVax Australia  (PaxVax) for the   intentional release of a  GMO vaccine   consisting of live bacteria into the environment in Queensland, South Australia, Western Australia and Victoria.

According to the regulator, it qualifies as a limited and   controlled release under section 50A of the Gene Technology Act 2000 (the Act).

PaxVax is seeking approval to conduct the clinical trial of a genetically modified live   bacterial vaccine against cholera. Once underway the trial is expected   to be completed within one year, with trial sites selected from local   government areas (LGAs) in Queensland, South Australia, Victoria and   Western Australia. PaxVax has proposed a   number of control measures they say will restrict the spread and persistence of the   GM vaccine and its introduced genetic material, however there is always a possiblity of these restrictions failing and infecting wildlife and ecosystems.
Aerial vaccines have used in the United States  directed towards animals by the use of plastic packets dropped by planes or helicopters. Sanofi (who is one of the largest vaccine manufacturers in the world) has subsidiary companies such as Merial Limited who manufacture Raboral, an oral live-virus poisonous to humans yet distributed wildlife in the masses.
In 2006 Michael Greenwood wrote an article for the Yale School of   Public Health entitled,  “Aerial Spraying Effectively Reduces Incidence   of West Nile Virus (WNV) in Humans.” The article stated that the   incidence of human West Nile virus cases can be significantly reduced   through large scale aerial spraying that targets adult mosquitoes,   according to research by the Yale School of Public Health and the   California Department of Public Health.
Under the mandate for aerial spraying for specific vectors that pose a   threat to human health, aerial vaccines known as DNA Vaccine   Enhancements and Recombinant Vaccine against WNV may  be tested or  used   to “protect” the people from vector infection exposures. DNA vaccine   enhancements specifically use Epstein-Barr viral capside’s with multi   human complement class II activators to neutralize antibodies. The    recombinant vaccines against WNV  use Rabbit Beta-globulin or the poly   (A) signal of the SV40 virus. In early studies of DNA vaccines it  was    found that the negative result studies would go into the category of   future developmental research projects in gene therapy. During the   studies of poly (A) signaling of the SV40 for WNV vaccines, it was   observed that WNV will lie dormant in individuals who  were exposed to   chicken pox, thus upon exposure to WNV aerial vaccines the potential for   the release of chicken pox virus would cause a greater risk to having   adult onset Shingles.


In February 2009 to present date, aerial spraying for the WNV   occurred in major cities within the State of California. During spraying   of Anaheim, CA a Caucasian female (age 50) was exposed to heavy   spraying, while doing her daily exercise of walking several miles. Heavy   helicopter activity occurred for several days in this area. After   spraying, she experienced light headedness, nausea, muscle aches and   increased low back pain. She was evaluated for toxicological   mechanisms that were associated with pesticide exposure due to aerial   spraying  utilizing advanced biological monitoring testing. The test   results which included protein band testing utilizing Protein Coupled   Response  (PCR) methods were positive for KD-45. KD-45 is the protein   band for SV-40 Simian Green Monkey virus. Additional tests were   performed for Epstein-Barr virus capside and Cytomeglia virus which are   used in bioengineering for gene  delivery systems through viral protein   envelope and adenoviral protein envelope technology. The individual was   positive for both; indicating a highly probable exposure to a  DNA   vaccination delivery system through nasal inhalation.

Pentagon Document Revealed Aerial Vaccination Plans
In the Quarterly FunVax Review in June, 2007,   the report lists the objective of a project listed as ID: 149AZ2 as a   preparation of a viral vector that will inhibit/decrease the expression   of a specific disruption gene (VMAT2) within a human population. It   further indicates in the abstract that six method of virus dispersal   were tested including high altitude release, water supply release,   insect transmission, and various methods of diffusion.